Rui Finance Deng RufeiJiangsu Hanbang Technology Co., Ltd. *** hereinafter referred to as "Hanbang Technology") recently disclosed the prospectus (declaration draft) for its initial public offering** and listing on the Science and Technology Innovation Board.
At the beginning of the reporting period, the shareholders of Hanbang Technology included 5 natural person shareholders Zhang Dabing, Zhang Zhoufeng, Gao Xuan, Ni Zhengdong and Li Shengying, 6 institutional shareholders Qingke Zhisheng, WuXi AppTec, Youxiang Hanrong, Tofflon Equipment, Qingke Co-creation and Xinhai Entrepreneurship, as well as 3 employee shareholding platforms H&Q Investment, Huai'an Jizhi and Huai'an Jicai.
During the reporting period, Hanbang Technology carried out a total of 5 capital increases and 6 equity transfers, and while the company pulled in new war investment to raise its valuation, some old shareholders took the opportunity to cash out.
In February 2020, Hanbang Technology ushered in the first capital increase during the period, and Junlian Xinkang won 1237110,000 yuan to subscribe for the new registered capital of 59620,000 yuan, with a capital increase of 2075 yuan registered capital, corresponding to the company's valuation of 41.2 billion yuan.
In September of the same year, WuXi AppTec, Legend and Industry, Sequoia Hanchen, Yida Ninghai, Huaishang Kaiyuan and Qizhen Future invested a total of 5,609870,000 yuan, of which, WuXi AppTec, Junlian Heye, Sequoia Hanchen, and Huaishang Kaiyuan all cost 1019970,000 yuan subscribed 19With a registered capital of 870,000 yuan, Yida Ninghai and Qizhen Future increased their capital by 453 respectively890,000 yuan, 1076080,000 yuan.
The capital increase** is 5132 yuan registered capital, corresponding to the company's valuation of 107.6 billion yuan, a significant increase of 161 from half a year ago17%。
Under the sharp rise in valuation, several old shareholders saw the opportunity to cash out. In the same month, Zhang Zhoufeng, Zhang Dabing, Tofflon Equipment, and Xinhai Venture cashed out 6,558 yuan respectively through equity transfer450,000 yuan, 2,305150,000 yuan, 1,336170,000 yuan, 1,895360,000 yuan, the transferee is the original shareholders WuXi AppTec New Pharmaceutical, Legend and Industry, Sequoia Hanchen, Yida Ninghai, Yida Innovation and the new shareholder Ganzhou Xinyuehu, each contributing 2,549940,000 yuan, 3,059930,000 yuan, 3,059930,000 yuan, 1586060,000 yuan, 819$290,000 and $1,019970,000 yuan.
A month later, there was a company like Hanrong that held 77010,000 yuan, 38The registered capital of 970,000 yuan is 5132 yuan of the registered capital, respectively, transferred to the employee shareholding platform Huai'an Huairong and Huai'an Jixin, with a total of 5,952 cash190,000 yuan after the withdrawal of shareholders; Gao Xuan, the company's supervisor, will hold 24The registered capital of 160,000 yuan was transferred to Huai'an Jixin, and 12.4 million yuan was cashed out.
In January 2022, the employee shareholding platform H&Q Investment held a registered capital of 240,000 yuan in the company with 3,090430,000 yuan was transferred to Langma No. 53, and the equity transfer ** was 12877 yuan registered capital, corresponding to the company's valuation of 2.7 billion yuan.
In April of the same year, Hanbang Technology, which completed the shareholding reform, soon carried out another round of financing, and Guoshou Quan, Guofa Science and Technology Innovation, and Heshi Investment were 14308 yuan of the total investment of the ** shares30.1 billion yuan, the company's valuation rose to 330.1 billion yuan.
In September 2022, Hanbang Technology implemented an equity incentive, with Huai'an Jixin and Huai'an Jili at 3469 yuan of ** capital to the company 2,462990,000 yuan, which is 143 more than the same period of war investment08 yuan shares hit 242% off.
From 2020 to the first half of 2023, the amount of share-based payments related to Hanbang Technology's equity incentive was 534640,000 yuan, 586940,000 yuan, 1659420,000 yuan and 730010,000 yuan, accounting for the proportion of the net profit attributable to the parent company in the current period. 04% and 2513%。
In December 2022, Hanbang Technology converted its capital reserve into share capital, and donated a total of 42.22 million shares based on the existing total share capital of 23.78 million shares, and the company's total share capital increased to 66 million shares after the transfer.
Before submitting the statement, WuXi AppTec, an old shareholder who made two additional investments in the company during the reporting period, finally cashed out once, and in March 2023, WuXi AppTec finally cashed out 91670,000 shares were transferred to Huajin Lingyue, and the equity transfer** was 5454 yuan shares, corresponding to the company's valuation of 3.6 billion yuan, compared with 41.2 billion yuan, an increase of 773 times.
At present, WuXi AppTec's new drug is rated at 805% of the shareholding ratio ranks among the second largest shareholders of Hanbang Technology. According to the data, WuXi AppTec is an A-share and Hong Kong-listed company WuXi AppTec (603259sh,02359.HK), which provides integrated new drug development and manufacturing services for the global biopharmaceutical industry, covering the fields of chemical drug development and cell and gene development.
Rui Caijing's "Pre-IPO" noted that WuXi AppTec is not only the second largest shareholder of Hanbang Technology, but also ranks among the company's major customers. From 2020 to the first half of 2023, Hanbang Technology and WuXi AppTec have related sales to a number of subsidiaries of WuXi AppTec, mainly for drug separation and purification equipment and related accessories, and laboratory instruments, with sales amounts of 382 respectively480,000 yuan, 775880,000 yuan, 2,151$10,000 and 604660,000 yuan. In 2022, WuXi AppTec became the company's third largest customer.